Exelixis, Inc. (EXEL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Exelixis, Inc. (EXEL) is up 17.2% since the beginning of the year. At $51 per share, EXEL is trading 4.8% below its 52-week high of $54. Investors who bought $1,000 worth of EXEL shares 5 years ago would now be looking at an investment worth $2,311.

Exelixis, Inc. (EXEL) has returned 17.16% so far this year and 27.20% over the past 12 months. Looking at the last ten years, EXEL has achieved an annualized return of 20.91%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Apr 17, 2000, EXEL's average daily return is +0.10%, while the average monthly return is +1.92%. At this rate, an investment would double in approximately 3.0 years.

Historically, 53% of months were positive and 47% were negative. The best month was Nov 2002 with a return of +83.4%, while the worst month was Sep 2014 at -63.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, EXEL closed higher 49% of trading days. The best single day was Jul 20, 2015 with a return of +50.4%, while the worst single day was Sep 2, 2014 at -55.3%.

Exelixis, Inc. has an annualized alpha of 15.26%, beta of 1.31, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since April 17, 2000.

• This stock captured 175.56% of S&P 500 Index gains and 157.39% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EXEL ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Exelixis, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Exelixis, Inc. was 97.38%, occurring on Dec 24, 2014. Recovery took 2859 trading sessions.

The current Exelixis, Inc. drawdown is 4.02%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Exelixis, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Exelixis, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.